Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer
| Autor: | Howard J. Lee, Ramesh Rengan, Jing Zeng |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
business.industry medicine.medical_treatment Review Article Disease Immunotherapy medicine.disease Immunoadjuvant Radiation therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer cell Cancer research Medicine Non small cell business Lung cancer Immune activation |
| Zdroj: | Translational Lung Cancer Research. 7:180-188 |
| ISSN: | 2226-4477 2218-6751 |
| DOI: | 10.21037/tlcr.2018.03.28 |
| Popis: | Proton beam therapy (PBT) is becoming an increasingly common option for patients undergoing radiation therapy (RT). With the concurrent emergence of immunotherapy as an effective systemic treatment for historically treatment-resistant disease such as advanced non-small cell lung cancer (NSCLC), the combination of RT’s immunoadjuvant effects with immunotherapy is gaining widespread attention. However, pre-clinical and clinical studies have shown potential immunosuppressive mechanisms associated with conventional RT that may restrict its immunogenic potential. Protons, as charged particles, exhibit both dosimetric and biological differences in normal and cancer cells that may be able to not only enhance the immunoadjuvant effects of RT, but also reduce immunosuppressive mechanisms. Here, we review the rationale, preclinical and clinical evidence, and ongoing efforts in combining PBT with immunotherapy in cancer treatment with a focus on NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|